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Research Article
Neoglycoproteins as carbohydrate antigens:
Synthesis, analysis, and polyclonal antibody
response
The analysis and polyclonal antibody response for newly synthesized maltose–BSA conju-
gate neoglycoproteins is described. In this first proof of concept study, a simple carbohy-
drate antigen, maltose, was linked to BSA by reductive amination. An aglycone spacer was
utilized to conserve the intact annular maltose structure and to promote the accessibil-
ity of the carbohydrate immunogen hapten during immunization. The neoglycoproteins
were investigated by CGE and the number of conjugated maltose residues was deter-
mined by MALDI-TOF MS. The neoglycoproteins were then evaluated by immunization
of BALB/c mice and the polyclonal antibody response was tested by ELISA as evidence
for the presence of sugar-containing epitope-specific antibodies. Selective antibody bind-
ing was demonstrated to the synthesized neoglycoproteins with different (low and high)
glycosylation degrees suggesting the possible use of this approach to generate antibodies.
Moreover, the polyclonal antibody response was not inhibited by maltose or other simple
carbohydrates to confirm presence of the neoglycoprotein-specific antibodies.
Keywords:
Carbohydrate antigen / Carbohydrate-specific antibody / ELISA / Neoglyco-
protein DOI 10.1002/elps.201300052
 Additional supporting information may be found in the online version of thisarticle at the publisher’s web-site
1 Introduction
Glycobiology and the study of glycoproteins became increas-
Q1
ingly important in the past few years [1–3]. Carbohydrate
moieties are predominant surface components of cells such
as erythrocytes, immune cells, microorganisms, etc., and
proved to be essential partners in many biological recogni-
tion processes [4]. Interactions of proteins or lipids with gly-
cans, namely complex oligosaccharides that are attached to
proteins or lipids, play a significant role in the antigen and/or
pathogen recognition machinery [5], malignant transforma-
tion [6], neurological disorders [7], etc. Naturally occurring
and adaptive antiglycan antibody development against car-
bohydrate antigens is of increasing importance since glyco-
sylation is recognized as a significant player in biomarker
Q2
Q3
research and discovery [8]. The anticarbohydrate antibodies
Correspondence: Professor Andra´s Guttman, Horva´th Laboratory
of Bioseparation Sciences, Medical and Health Science, Univer-
sity of Debrecen, Debrecen, Hungary
E-mail: guttman.andras@hlbs.org
Fax: +36-52-414-717-55539
Abbreviations: mCGE, Multicapillary gel electrophoresis;
PGA, printed glycan array
can be useful as diagnostic markers for detecting carbohy-
drate antigens in various diseases [9]. Moreover, anticarbohy-
drate antibodies hindering or promoting therapeutic poten-
tialmay occur as neoglycoprotein-based antibacterial vaccines
or neoglycoprotein-based antitumor vaccines for cancer [10].
The advent of anticarbohydrate antibodies such as antilami-
naribioside and antichitobioside holds the promise to detect
glycans, which are characteristic for various diseases [1, 4].
Neoglycoproteins as sugar-specific antigens were first
used as vaccines as early as in 1931 by Avery and Goebel [11],
and since then they have been utilized in a wide variety of
applications, such as diagnostic markers [12] as immune re-
sponse triggers antitumor-associated carbohydrate antigens
[13]. With their possible oncogenic role recognized, naturally
occurring sugar-specific antibodies seem to play an impor-
tant part in antitumor surveillance, probably by binding to the
repetitivemotif of carbohydrate epitopes [14]. Meanwhile, dif-
ferential glycosylation is a hallmark of tumor-associated car-
bohydrate antigens [15]. Cancer-associated carbohydrates are
mostly located on the surface of cancer cells and represent
potential targets for new diagnostic assays and therapeutic
treatments [16]. Antiglycan autoantibodies in their possible
∗These authors contributed equally to this work.
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malignancy-defining role have been first described in breast
cancer and Hodgkin’s lymphoma [17]. The synthesis of neo-
glycoproteins primarily involves random or defined coupling
sites on the surface of the carrier protein, which is covalently
modified with glycans via their reducing end or functional-
ized glycan bearing spacer arms [10,18,19]. Complex carbohy-
drates and neoglycoproteins are routinely used for a variety of
biological assays. Currently, the most frequently used glycan-
based assays are printed glycan array (PGA), multiplex flow
cytometric suspension assay, and ELISA. Although, the con-
ventional ELISA technique provides assessment of a limited
number of glycan–protein interactions, it is still the most
widely used method for this type of application [20, 21]. PGA
is one of the newest high-throughput microarray techniques
that enable studying biomolecular interactions [22, 23]. Both
in ELISA and PGA, the interrogating sugar structures are lo-
cated on a flat surface. In PGA, sugars are covalently attached
to the surface of a glass slide in a monovalent form as -alkyl
glycosides (Glyc-sp-NH2), whereas in ELISA they are physi-
cally absorbed to polystyrene in multivalent form, as conju-
gates with a polyacrylamide or albumin carrier [24]. The exis-
tence of naturally occurring antiglycan autoantibodies [17,23]
suggests that although not widely anticipated, elicitation of
specific antibodies to defined glycansmay be possible. An ob-
vious application of glycan-specific polyclonal or monoclonal
antibodies is biomarker discovery via comprehensive and spe-
cific detection of disease-specific glycosylation changes. In the
future, these sugar-specific antibodies may provide sensitive
and specific complementary assays to the currently used PGA
and ELISA methods.
CGE in the presence of SDS is a widely used method
for the separation and analysis of glycoproteins, which of-
fers high resolving power and rapid separation times [25–27].
Moreover, CGE represents many advantages over classical
SDS-PAGE including automation, on-column direct UV,
LIF, or LED-IF detection options and accurate quantifica-
tion of biopolymers [28]. Another alternative is microfluidic
chip based electrophoresis methods that provide significantly
shorter analysis times, but frequently suffers from limited
resolution due to the short separation channel length. Mul-
ticapillary gel electrophoresis (mCGE) with LED-IF, on the
other hand, is reportedly applicable to rapid and large-scale
analysis of biomolecules [29]. Another important tool for
structural analysis of carbohydrates is MS that offers precise
molecular mass data, analytical versatility, and good sensitiv-
ity [30]. MALDI was successfully developed as a soft ioniza-
tion method for biopolymer analysis less than two decades
ago. This technique is capable of direct mass measurement
of high molecular weight compounds such as synthetic poly-
mers, proteins, oligonucleotides, or complex carbohydrates
[31].
In this paper, we report on the synthesis and CE (mCE)
as well as MALDI-TOF MS analysis of neoglycoproteins
(maltose-conjugated BSA) and results are presented on their
ability to elicit specific immune response. BSA was chosen
as a carrier since in its natural form it voids glycosylation.
Neoglycoproteins were synthesized under controlled condi-
tions with different numbers of oligomeric/ dimeric maltose
molecules (between 32 and 66 units/mol) conjugated to the
lysine -amino residues of BSA. The polyclonal antibody re-
sponse was evaluated in mice. Adaptation of this approach
as good working model was planned for conjugation of com-
plex disease specific sugar structures to carriers in order to
generate printed antiglycan microarrays.
2 Experimental methods
2.1 General procedures
All reagents and chemicals for the synthesis of neoglyco-
proteins and the general reagents for CE, MALDI-TOF MS,
and ELISA tests were purchased from Sigma-Aldrich (St.
Louis, MO, USA). TLC was performed on Kieselgel 60 F254
precoated aluminum plates (Merck, Darmstadt, Germany).
Compounds were visualized by treating the plates with 10%
H2SO4 and heating to 140C. Column chromatography was
performed with Kieselgel 60 (Merck, 0.063–0.2 mm) with
solvents specified under the relevant sections. After extrac-
tion, all organic phases were concentrated in a rotary vacuum
evaporator (Bu¨chi Rotavapor R-114, Flawil, Switzerland). The
uncorrected melting points were determined by a Kofler ap-
paratus (Dresden, Germany). NMR spectra were recorded
on a Bruker (Bremen, Germany) DRX-360 instrument (1H
360.13 MHz, 13C 90.56 MHz) at room temperature in CDCl3
solvent, using Me4Si as internal standard (see Supporting
Information).
2.2 Synthesis of neoglycoproteins
Acetylation step: All theOHgroups ofmaltosewere acetylated
by acetic anhydride and sodium acetate to yield crystalline
compound, 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl-(1→4)-
1,2,3,6-tetra-O-acetyl--D-glucopyranose. Deprotection step:
After that the anomeric OH group of maltose oc-
taacetate was deprotected by hydrazine-acetate and
then 2,3,4,6-tetra-O-acetyl--D-glucopyranosyl-(1→4)-2,3,6-
tri-O-acetyl--D-glucopyranose compoundwas converted into
the corresponding trichloroacetimidate donor.
Spacer addition step: The trichloroacetimidate donor was
reacted with the 7-(1,3-dioxan-2-yl)-heptan-1-ol spacer. Con-
jugation step: The synthesized product was deprotected and
then the functionalized maltose was conjugated into BSA by
reductive amination to form neoglycoprotein. See details in
Supporting Information.
Please note that a formyl-heptyl spacer was used at the
reducing end of the carbohydrate hapten [32,33] to minimize
the risk of introducing a stronger immunogen close to the
sugar residue, i.e. this spacer contains no functional groups
in the vicinity of the carbohydrate. The coupling reactions
were performed for different rations hapten-spacer/BSA, so
different neoglycoproteins were obtained (BSA-32-maltose,
BSA-50-maltose, BSA-59-maltose, and BSA-66-maltose), re-
spectively. See details in Supporting Information.
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2.3 Fluorophore labeling and CGE analysis of
neoglycoproteins
For neoglycoprotein labeling, the fluorescent reagent
Chromeo P503 (Active Motif; Rixensart, Belgium) was dis-
solved in methanol in a final concentration of 1 mg/mL
and the stock solution was kept at 4C. The synthesized gly-
coconjugates were diluted in MilliQ-grade water (Millipore,
Billerica, MA, USA) in a final concentration of 2 mg/mL. A
total of 5 L of each sample was transferred to a 200-L PCR
tube for the SDS-mCGE analysis followed by the addition of
2 L of 0.5 M DTT reducing agent, 0.5 L of 1 mg/mL dye
stock solution, 2.5 L of 10% SDS, and 25 L of 25 mM
NaHCO3 buffer (final concentration: 17.86 mM; pH 9.20) to
a total volume of 35 L and incubated at 90C for 30 min.
The samples were then allowed to cool to ambient tempera-
ture and centrifuged at 3000 × g for 30 s (Centrifuge 5424,
Eppendorf, Hamburg, Germany) prior to themCGE analysis.
TRIS–borate (60 mM) containing 0.1% SDS (pH 8.45) buffer
was used as BGE in all electrophoretic analysis. The sample
buffer contained 25 mM NaHCO3 and the pH was adjusted
to 9.2 by the addition of 0.1MNaOH. All buffers and reagents
were filtered through 0.22 m pore size Acrodisc (Millipore)
syringe filters and degassed before use.
All separations were performed in a P/ACE MDQ CE
system (Beckman Coulter, Brea, CA, USA). The unit was
equipped with a 488-nm Ar-ion laser having a strong 514-nm
line and the emission signal was collected through a 600-nm
long pass filter. The separation capillary (10 cm effective
length and 30 cm total length, 75 m id) was first rinsed with
water, then 0.1 M HCl, and flushed again with water before
the SDS-MW gel buffer (Beckman Coulter) was transferred
into the capillary. Prior to each injection, the sieving matrix
was replaced in the column. The sample injection process
was preceded by the introduction of an HPLC-grade water
plug (12.5 kV for 5 s). The samples were introduced elec-
trokinetically at the short side of the capillary (10 cm) from
a 96-well plate (25 kV for 10 s). All separations were carried
out at 25C by applying 500 V/cm electric field strength. The
Karat 32 version 7.0 software package (Beckman Coulter) was
used for data acquisition and analysis.
2.4 Analysis of neoglycoproteins by MALDI-TOF MS
MALDI-TOF MS based molecular mass assessment of the
synthesized neoglycoproteins was carried out in positive
reflectron mode using a BIFLEX III mass spectrometer
(Bruker) with delayed-ion extraction. Spectra from multiple
(> 100) laser shots (N2 laser, 337 nm) using 19 kV accelerating
and 20 kV reflectron voltage were summarized. External cali-
brationwas applied using BSA (6–8mg/mL in 0.1%TFA). TA
solution was prepared by dissolving 0.1% TFA in a mixture
of 2:1 ACN–water. A total of 10 L of sample, 25 L matrixQ4
(3,5-dimethoxy-4-hydroxycinnamic acid), and 15 L TA solu-
tion were mixed and 0.5 L was applied to the target plate
and allowed to dry at room temperature before analysis.
2.5 Immunization with neoglycoproteins
For each immunization step (BALB/cmouse  , Charles River
Hungary, Isaszeg, Hungary), both the lowest (32 units/mol)
and highest (66 units/mol) amount of sugar-incorporated
synthetic neoglycan immunogens (50 g/mL in phosphate
buffered saline, pH 7.4) were mixed with equal volume of
Freund’s complete adjuvant and incomplete Freund’s adju-
vant for the first and consecutive immunization injections,
respectively. The mixture was injected subcutaneously into
the hindfeet of themice three times in 2-week intervals. Seven
to ten days after the third injection, blood was taken from the
eye corners of the mice. The serum was separated from the
red blood cells and tested by ELISA.
2.6 Analysis of carbohydrate-speciÞc antibodies
with ELISA
Immunoassay plates (Corning 96-well plates, half-area clear
polystyrene, high-binding, nonsterile, Sigma-Aldrich) were
coated with synthetic neoglycoprotein as immunogens, 30L
per well in the coating buffer of 14.7 mM Na2CO3, 34.9 mM
NaHCO3, pH 9.6, and incubated at 37C for 1 h. A to-
tal of 10 g/mL and a twofold serial dilution from 1.25
to 0.08 g/mL of immunogen coatings were used to de-
tect the polyclonal antibody response, and 0.2 g/mL BSA
and synthetic neoglycoprotein as immunogen coatings were
prepared for the experiments, which were done in the pres-
ence of inhibitors. The plates were washed twice with PBS-
TWEEN wash buffer (123.2 mM NaCl, 3.2 mM KH2PO4,
10.5 mM Na2HPO4, 0.05 v/v% Tween-20, pH 7.2), the re-
maining protein-binding sites were blocked by the addition
of 60 L PVP-blocking buffer (376.5 mM NaCl, 0.5 m/v%
polyvinyl-pyrrolidone in the PBS-TWEEN buffer) and incu-
bated at 37C for 30 min. Then, the plates were washed twice
with wash buffer and 30 L of appropriately diluted immune
sera was added to each well followed by incubation at 37C
for 1 h. Serum dilutions of 1000–128 000× were used to
check the polyclonal antibody response. Then, the plates were
washed four times with the wash buffer. This was followed
by washing the plates four times with wash buffer before
30 L of appropriately (8000-fold) diluted horseradish per-
oxidase (HRP-labeled) conjugated secondary antibody (goat-
anti-mouse IgG, Southern Biotechnology, Birmingham, AL,
USA) was added to each well and incubated at 37C for 30
min. To measure the bound antibody, 30 L of 3,3′,5,5′-
tetramethylbenzidine substrate solution was added to each
well. This solution consisted of 3,3′,5,5′-tetramethylbenzidine
tablet dissolved in the mixture of 1 mL DMSO and 9 mL
citrate-phosphate buffer (52.0 mM Na2HPO4, 25.5 mM cit-
ric acid, pH 5.0). A total of 2 L of fresh 30% hydrogen
peroxide was added per 10 mL of substrate buffer solution
immediately prior to use. The estimated incubation times
for the enzyme-substrate reaction ranged from 10 to 15 min,
after which 30 L stop solution (4 M H2SO4) was added to
the reaction and the plates were interrogated at 450 nm in
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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a Multiscan Ascant reader (Thermo Scientific, Hudson, NH,
USA).
In the inhibition studies, 0.1–1.6 g/mL BSA, neogly-
coproteins, and 2.00–0.06 mg/mL maltose, glucose, isomal-
tose, lactose, galactose, and maltodextrin were used to inhibit
the binding of specific antibodies from the suitably diluted
(2000-fold) plasma preparations. 4000-fold dilution of sera
was prepared without inhibitors as control. After coating and
blocking, the serum was mixed with an equal volume of the
inhibitor. The mixture was placed on the well and incubated
for 1 h at 37C. This was followed by washing the plates
four times with wash buffer before 30 L of appropriately
(8000-fold) diluted horseradish peroxidase (HRP labeled) con-
jugated secondary antibody (goat-anti-mouse IgG, Southern
Biotechnology) was added to each well and incubated at 37C
for 30 min. Then the plates were washed four times with the
wash buffer. Antibody binding was measured as described
above.
3 Results and discussion
3.1 Neoglycoprotein synthesis
The synthesis of carbohydrate hapten for the generation of
the neoglycan immunogen started with reactingmaltose with
acetic anhydride to form the maltose octaacetate, followed by
the removal of the anomeric acetyl group to yield the hemi-
acetal anomers. The anomeric configuration was verified by
NMR (see Supporting Information). The resulted hemi-acetal
was transformed to a trichloroacetimidate donor and then re-
acted with the aglycone spacer of 7-(1,3-dioxan-2-yl)-heptan-1-
ol to form a protected maltose with the formyl-heptyl spacer.
Before the conjugation step, the protecting acetal group and
acetyl groups were removed and the resulting aldehyde was
linked to the lysine -amino groups of BSA to form the Schiff
base, which was consequently reduced with NaCNBH3 to
obtain a stable neoglycoprotein that served as synthetic car-
bohydrate hapten of the immunogen.
3.2 CGE and MALDI-TOF MS analysis of
neoglycoproteins
The reaction resulted in different number of sugar residues
on the BSA molecules. The reaction products were first an-
alyzed by capillary SDS gel electrophoresis for purity and
homogeneity. Figure 1 depicts the capillary SDS gel elec-
trophoresis traces showing the unconjugated dye (first peak
at 10 min) and the generated conjugates (second peak), hav-
ing 32, 50, 59, and 66 units/mol maltose units as determined
by MALDI-TOF MS (see below). One can observe the longer
migration times and suppressed signal intensity of the con-
jugates with increasing sugar unit content. The former is due
to the effect of the larger molecular mass of the conjugates
with the attached maltose residues and the concomitantly
suppressed SDS binding to these hydrophilic patches, both
Figure 1. Typical CGE analysis of covalently fluorophore tagged
and reduced glycoconjugate samples. Peaks: (1) remaining label-
ing dye, (2) maltose-conjugated BSA. Separation conditions: bare
fused silica capillary (effective length: 10 cm; total length: 30 cm,
75 m id); BGE: SDS-MW gel buffer (Beckman Coulter); applied
electric field strength: 500 V/cm; electrokinetic injection: 25 kV for
10 s; separation temperature: 25C.
causing migration time increase. The decreasing signal in-
tensity of the conjugate (and the increasing signal intensity
of the unconjugated free dye) with the increasing maltose
content is due to the reduced number of available conjuga-
tion sites for the fluorescent dye, i.e. remaining free amino
residues on BSA.
The exact number of conjugated maltose units was de-
termined by MALDI-TOF MS as shown in Table 1. Please
note that by increasing the molar ratio of the disaccharides to
BSA, the incorporation level of sugars increased from 32 to
66 units. Since BSA only contains 60 free amino groups, as a
first approximation we considered that in some instances ter-
tiary amineswere formedduring the reductive amination step
acquiring two sugar structures [34], consequently increasing
the number of conjugated glycans beyond 60.
3.3 Polyclonal antibody response elicited by
neoglycoproteins
Using neoglycoproteins with low and high sugar incorpora-
tion levels (32 and 66maltose units per BSA) as immunogens,
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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Table 1. Analysis of the number of conjugated sugar residues in the synthesized antigens by MALDI-TOF MS and parameters of the
conjugation step
Neoglycoproteins
BSA-32-maltose BSA-50-maltose BSA-59-maltose BSA-66-maltose
Maltose containing spacer (mM) 0.025 0.05 0.075 0.15
Acetic acid (mL) 1.18 2.36 3.54 7
Water (mL) 0.3 0.6 0.9 1.8
Phosphate buffer (mL) 2 2 2 2
BSA (nM) 250 250 250 250
NaCNBH3 (mM) 0.050 0.1 0.15 0.3
Amount of antigens (mg) 4.5 19.2 9.9 18.6
MALDI-TOF MS (Da)a) 80 851.1 88 854.5 93 171.6 96 258.5
Carbohydrate units 32 50 59 66
a) Sugar-spacer (C20H35O11):451 Da; BSA: 66 401 Da; Calculation: (80 851 – 66 401)/451 = 32 units.
Figure 2. Polyclonal antibody response against the protein carrier and the synthesized neoglycoproteins. Antiglycan antibodies produced
by immunization with BSA-32-maltose (Panels A and C) and BSA-66-maltose (Panels B and D) incorporated sugar-containing neogly-
coproteins detected by ELISA. Experiments were done either by using a fixed amount of immobilized antigens (10 g/mL); and serial
(1000–128 000×) dilutions of immune-sera (Panels A and B), or by using serial dilution of immobilized antigens (from 1.25 to 0.08 g/mL)
and 4000-fold dilution of the sera.
BALC/c mice were immunized and the polyclonal antibody
response, specific for the carriermolecule and the sugar com-
ponent of the immunogen, was analyzed by ELISA. In mice,
immunized with the BSA-32-maltose, a rather unified re-
sponse was observed toward the different immunogens, as
shown Fig. 2, panel A. In mice, immunized with the BSA-
66-maltose, the IgG response was more intense toward the
modified immunogens and was distinguishable from that of
the significantly weaker carrier-specific response as shown
Fig. 2, panel B. This difference was even more pronounced
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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Figure 3. Specificity of the antiglycan antibody response. Inhibition studies of antiglycan antibody binding to their antigens using BSA
(Panel A), BSA-32-maltose (Panel B), and BSA-66-maltose (Panel C) sugar incorporated glycoproteins as inhibitors. Antibodies (4000×
serum dilutions, immunized with high sugar incorporated antigens in mice) were examined with all three coatings (0.2 g/mL) in the
presence of BSA inhibitor (0.1–1.6 g/mL); BSA-32-maltose and BSA-66-maltose neoglycoprotein inhibitors (0.1–1.6 g/mL).
when the experiment was conducted under immunogen lim-
iting conditions. Panels C and D reveal that in the presence of
limited amount of immunogen, a more significant antibody
response could be observed against neoglycoproteins than
against the carrier proteins, although the difference might
vary depending on the immunogen used for immunization
or even on the response of the individual animal. However,
our results suggested that antibody populations specific for
the neoglycoproteins were present in the mouse immune
sera.
3.4 Inhibition of mouse antibody binding to
neoglycoproteins
Inhibition experiments (ELISA) were performed in order to
test the specificity of the polyclonal antibody response to the
synthetic neoglycoproteins. The polyclonal antisera were re-
acted with immobilized BSA-32-maltose and BSA-66-maltose
in the presence of inhibitors and Fig. 3 shows the results. Re-
sponse to each immunogen, namely BSA, BSA-32-maltose,
and BSA-66-maltose, was specifically inhibited by the corre-
sponding immunogens, i.e. BSA-specific response was inhib-
ited by BSA (Panel A), BSA-32-maltose-specific response was
inhibited by BSA-32-maltose (Panel B), and BSA-66-maltose-
specific response was inhibited by BSA-66-maltose (Panel C).
In addition, BSA-32-maltose inhibited BSA-specific response
(Panel B), while BSA-66-maltose inhibited both BSA- and
BSA-32-specific responses (Panel C). However, none of the
reactions could be inhibited by free maltose and other sugars
such as glucose, isomaltose, lactose, galactose, and maltodex-
trin (data not shown), suggesting that the synthesized neo-
glycoproteins contained specific epitopes that were unique to
the presence of the defined number of conjugated maltose
units per BSA molecules. The results suggest that immuno-
genic neoepitopes were induced by maltose conjugation
and increase in the maltose units from 32-maltose/BSA to
66-maltose/BSA resulted in the appearance of new epitopes
not present on the BSA-32-maltose molecules. It remains
to be determined, however, whether the new immunogenic
epitopes included the sugar component or merely repre-
sented conformational changes of the core polypeptide chain
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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induced by the sugar conjugation process. Nevertheless,
it is anticipated that clonal analysis of the polyclonal re-
sponse would identify mABs that recognize new sugar hap-
ten specific epitopes where the synthetic sugar residue is a
key component with respect to neoglycoprotein-specific IgG
binding.
4 Conclusions
In this paper, we have demonstrated that custom synthe-
sized neoglycoproteins could be utilized as immunogens to
generate polyclonal antibodies against the neoepitopes. Sur-
prisingly, the majority of epitopes detectable by polyclonal
mouse antisera on native BSA were preserved by the con-
jugation process and/or by the attachment of oligomeric
maltose molecules. In addition, specific antigenic epitopes
were induced by conjugation of 32 maltose molecules and
also by 66 maltose molecules, but the polyclonal antibody re-
sponse to these neoepitopes was not inhibitable by maltose
(or other simple or oligomeric sugars like glucose, isomal-
tose, lactose, galactose, and maltodextrin). The preliminary
studies reported here enable to formulate a hypothesis and
construct model systems that will allow further exploration of
glycosylation-induced changes in protein structure and func-
tion. We propose that (i) glycosylation may not influence the
majority of the antigenic epitopes, thus the overall structure
of proteins may remain intact; (ii) glycosylation induces anti-
genic epitopes that are apparently independent of the native
epitopes; (iii) in the majority of antibody responses to gly-
coproteins, key complementarity determining component of
the immunogen may not be the sugar. Please note that we
found no report in the literature suggesting that the core
protein structure was changed by glycosylation changes. On
the other hand, as disease-specific glycosylation changes have
been widely reported, it would be desirable to obtain specific
reagents that detect epitopes, which include the sugarmoiety.
Based on our current, and previous results, we suggest that
it may be possible to obtain strictly maltose-specific mAbs by
generating sufficiently large monoclonal antibody libraries
via mAb proteomics [35]. However, as only few strictly sugar-
specific mAbs have been reported in the literature [36,37], we
feel that the likelihood of obtaining such reagents is relatively
low.We have to add that through extensive search in the liter-
ature, we were not able to find polyclonal antibody response
to neoglycans with detectable specificity directed strictly to
the sugar moiety.
The question still remains to be answered whether the
structures of interest, in this particular study against maltose,
play a critical role in inducing novel epitopes. For this pur-
pose, the antibody response should be analyzed at the clonal
level. Thus, based on our encouraging preliminary results, we
plan to continue this work by conjugating complex disease-
specific sugar haptens to carriers with the goal to generate
monoclonal antibody libraries for the discovery of mAbs in
normal and disease models, with unique sugar specificities
that can be readily applied to biomedical research and clinical
diagnostics with the possible utilization of this approach to
generate printed carbohydrate antibody microarrays.
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